Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Update

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 1,370,000 shares, a drop of 21.3% from the January 15th total of 1,740,000 shares. Based on an average trading volume of 3,200,000 shares, the short-interest ratio is presently 0.4 days.

Institutional Investors Weigh In On Aethlon Medical

A number of institutional investors have recently modified their holdings of AEMD. Allegiance Financial Group Advisory Services LLC acquired a new position in shares of Aethlon Medical in the fourth quarter worth $26,000. Virtu Financial LLC purchased a new position in Aethlon Medical in the fourth quarter valued at about $81,000. Renaissance Technologies LLC acquired a new position in Aethlon Medical in the 4th quarter worth about $25,000. Sassicaia Capital Advisers LLC acquired a new stake in shares of Aethlon Medical during the 4th quarter valued at about $31,000. Finally, Boothbay Fund Management LLC acquired a new position in Aethlon Medical in the fourth quarter worth approximately $186,000. Institutional investors and hedge funds own 1.99% of the company’s stock.

Aethlon Medical Trading Down 2.5 %

Shares of NASDAQ AEMD opened at $0.62 on Friday. Aethlon Medical has a one year low of $0.24 and a one year high of $1.85. The business has a 50-day moving average price of $0.63 and a two-hundred day moving average price of $0.48. The firm has a market capitalization of $8.59 million, a PE ratio of -0.22 and a beta of 1.88.

Aethlon Medical (NASDAQ:AEMD) last posted its quarterly earnings results on Wednesday, February 12th. The medical equipment provider reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.09. Research analysts anticipate that Aethlon Medical will post -1.01 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. StockNews.com assumed coverage on shares of Aethlon Medical in a research report on Monday, January 27th. They issued a “sell” rating for the company. HC Wainwright restated a “buy” rating and issued a $7.00 target price on shares of Aethlon Medical in a report on Thursday, January 30th.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.